https://www.selleckchem.com/pr....oducts/trastuzumab-d
RESULTS Eleven eyes were enrolled in this study. Significantly, better BCVA was observed at 12 months than at baseline (P = 0.01. The mean CFT significantly decreased from 331 ± 93 to 237 ± 72 μm at 12 months (P less then 0.001). The mean CCT also significantly decreased from 361 ± 74 to 310 ± 83 μm at 12 months (P less then 0.001). The mean number of injections per eye was 3.9 ± 1.3 during the follow-up period. A total of 45.5% (5 /11) of the patients required retreatment during the maintenance phase. CONCLUSION An
Like
Comment
Share
